First Sale of New Product Line
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
Inaphaea is delighted to confirm customer shipment of its first batch of Patient Derived Cells ("PDCs"). The cells are provided as part of Inaphaea's new range of Assay Ready Reagents ("ARR"). The ARR range can be used directly for assays without the need to grow inhouse by the customer. Although the value of the order is not material, it endorses Inaphaea's product offering and a potential revenue source for the Company.
Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented "ARRs are a great new addition to our range of PDC products and services. They provide convenient access to mixed cell populations from our extensive biobank of over 450 PDCs in a ready to assay format."
Mark Eccleston, CEO of ValiRx commented "This first sale of our new product range is a major milestone for our commercialisation efforts."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.